التفاصيل البيبلوغرافية
| العنوان: |
Sarcopenia in Men With Bone-Predominant Metastatic Castration-Resistant Prostate Cancer Undergoing Ra-223 Therapy. |
| المؤلفون: |
Khan, Maira, Parshad, Shruti, Naimi, Mahdi F., Sidhu, Amanjot K., Lyons, Frank, Hardisty, Michael R., Whyne, Cari M., Smoragiewicz, Martin, Phillips, Cameron M., Briones, Juan, Emmenegger, Urban |
| المصدر: |
Clinical Genitourinary Cancer; Aug2023, Vol. 21 Issue 4, pe228-e235, 9p |
| مصطلحات موضوعية: |
CASTRATION-resistant prostate cancer, PROSTATE cancer treatment, RADIUMTHERAPY, DENOSUMAB, COMPUTED tomography |
| مستخلص: |
There are complex interactions between bone and skeletal muscle. However, the prevention and treatment of treatment-induced osteosarcopenia in men with metastatic castration-resistant prostate cancer focuses predominantly on bone health. In a single-center cohort of 52 patients we demonstrate that bone-targeted Radium-223 therapy does not accelerate sarcopenia, but baseline sarcopenia is associated with poor survival in such patients. Introduction: Osteosarcopenia is the progressive loss of musculoskeletal structure and functionality, contributing to disability and mortality. Despite complex interactions between bone and muscle, osteosarcopenia prevention and treatment in men with metastatic castration-resistant prostate cancer (mCRPC) focuses predominantly on bone health. It is unknown whether Radium-223 (Ra-223) therapy affects sarcopenia. Methods: We identified 52 patients with mCRPC who had received Ra-223 and had a baseline plus =1 follow-up abdominopelvic CT scan. The total contour area (TCA) and averaged Hounsfield units (HU) of the left and right psoas muscles were obtained at the inferior L3 endplate, and the psoas muscle index (PMI) was calculated there from. Intrapatient musculoskeletal changes were analyzed across various time points. Results: TCA and PMI gradually declined over the study period (P = .002, P = .003, respectively), but Ra-223 therapy did not accelerate sarcopenia, nor the decline of HU compared to the pre-Ra-223 period. The median overall survival of patients with baseline sarcopenia was numerically worse (14.93 vs. 23.23 months, HR 0.612, P = .198). Conclusions: Ra-223 does not accelerate sarcopenia. Thus, worsening muscle parameters in men with mCRPC undergoing Ra-223 therapy are attributable to other factors. Further research is needed to determine whether baseline sarcopenia predicts poor overall survival in such patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical Genitourinary Cancer is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
